ArticleMedecine tropicale et sante internationale2024
[Profile of fungal species involved in superficial cutaneous mycoses in Lomé (Togo)].
Article in Medecine tropicale et sante internationale, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The diagnosis of superficial cutaneous mycosis (SCM) is very frequently evoked during dermatological consultations in tropical zones, but mycological confirmation is very rarely performed routinely. The aim of this study is to describe the profile of fungal species encountered during dermatology consultations in Lomé (Togo), to establish their relative frequencies and, above all, to discuss their responsibility in the lesions observed. Method: This was a descriptive study carried out from February 2020 to March 2022, involving patients presenting lesions suspected of MCS, seen in dermatological consultations. Three dermatological consultation centers, all located in the city of Lomé, served as the setting for case enrollment. Each patient consulted who met the inclusion criteria (i.e. presenting a lesion of SCM and not under antimycotic treatment or having respected an adequate therapeutic window) had a sample taken from the suspected lesion(s). Samples were taken on site and analyzed at the Mycology Laboratory of CHU Sylvanus Olympio for biological confirmation. Results: During the study period, 565 patients were enrolled and sampled, of whom 364 (64.4 %) were women. The median age was 31 years, with interquartile range (IQR) from 22 to 41 years. Direct examination and/or culture were positive in 84.7 % (479/565) of cases. The main fungal species identified were yeasts (63%), including Conclusion: The spectrum of fungi isolated in suspected cases of SCMs in Lomé is broad, but not all can be held responsible for the lesions observed. This diversity makes it essential to take a mycological sample for accurate identification of the fungus in any suspected case of SCM. Depending on the species isolated, this will enable treatment to be tailored to the patient's needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.